Drug intelligence / Profile preview

ULK1i

Development stage: Preclinical
Lead developer: Txinno Bioscience
Modality: Small Molecules

Overview

ULK1i is a preclinical small-molecule inhibitor developed by Txinno Bioscience that targets Unc-51 Like Autophagy Activating Kinase 1 (ULK1). ULK1 is a serine/threonine kinase that plays a critical role in the initiation of autophagy, a cellular self-recycling process that cancer cells utilize to survive under metabolic stress and nutrient deprivation. By inhibiting ULK1, this therapy aims to exploit the intrinsic vulnerability of RAS-mutated cancers, such as pancreatic, colorectal, and lung cancers, which are highly dependent on autophagy for tumor maintenance and progression. The program is currently in the lead optimization phase and is being developed in collaboration with various partners, including the Korea Drug Development Fund (KDDF).

Other names: ULK1 inhibitor (Txinno Bioscience)

Targets

ULK1

Beyond the preview

Go deeper on ULK1i.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ULK1i.

Explore the full profile